Department of Cardiology and Vascular Medicine, West German Heart and Vascular Centre Essen, University Hospital Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Institute for Experimental Cardiology, University Hospital Heidelberg, Heidelberg, Germany.
Clin Res Cardiol. 2020 Oct;109(10):1197-1222. doi: 10.1007/s00392-020-01636-7. Epub 2020 May 13.
The acute and long-lasting side effects of modern multimodal tumour therapy significantly impair quality of life and survival of patients afflicted with malignancies. The key components of this therapy include radiotherapy, conventional chemotherapy, immunotherapy and targeted therapies. In addition to established tumour therapy strategies, up to 30 new therapies are approved each year with only incompletely characterised side effects. This consensus paper discusses the risk factors that contribute to the development of a potentially adverse reaction to tumour therapy and, in addition, defines specific side effect profiles for different treatment groups. The focus is on novel therapeutics and recommendations for the surveillance and treatment of specific patient groups.
现代多模式肿瘤治疗的急性和长期副作用显著降低了恶性肿瘤患者的生活质量和生存率。这种治疗的关键组成部分包括放疗、常规化疗、免疫疗法和靶向治疗。除了既定的肿瘤治疗策略外,每年还有多达 30 种新疗法获得批准,而这些新疗法的副作用只有不完全描述。本共识文件讨论了导致肿瘤治疗潜在不良反应发展的风险因素,并为不同治疗组定义了特定的副作用特征。重点是新型治疗方法以及对特定患者群体进行监测和治疗的建议。